News

Inside the deal: Roche and Zealand Pharma's $5.3 billion obesity drug gambit
The ballooning obesity drug market may have a new contender after Roche struck a $5.3 billion deal to develop Danish biotech ...
Eli Lilly downplays CVS move to drop Zepbound coverage, shares plunge
Eli Lilly on Thursday downplayed CVS Health's decision to drop the company's obesity drug Zepbound from some lists of ...
CVS Caremark To Place Novo Nordisk's Wegovy On Preferred Coverage For GLP-1 Weight Loss Treatment
Wegovy to become preferred GLP-1 drug on CVS Caremark's top formularies in 2025 as Novo Nordisk expands patient access ...
Nasdaq23h
Eli Lilly and Company Common Stock (LLY)
Real time quote data is not available at this time. *Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change. **Green ...